34
Participants
Start Date
March 16, 2015
Primary Completion Date
June 1, 2020
Study Completion Date
June 1, 2020
LUM001 (Maralixibat)
Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
The Children's Hospital of Philadelphia, Philadelphia
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
Baylor College of Medicine/Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
Children's Hospital Los Angeles, Los Angeles
University of California at San Francisco Children's Hospital, San Francisco
Seattle Children's Hospital, Seattle
The Hospital for Sick Children, Toronto
Lead Sponsor
Collaborators (1)
Lumena Pharmaceuticals, Inc.
INDUSTRY
Childhood Liver Disease Research and Education Network
OTHER
Mirum Pharmaceuticals, Inc.
INDUSTRY